Patient characteristics. BASDAI inflammation refers to the mean of BASDAI questions 5 and 6.
| Baseline Characteristics | Total, n = 20 |
|---|---|
| Age, yrs, mean ± SD | 46.2 ± 7.3 |
| Male, n (%) | 15 (75) |
| DMARD use at baseline, n (%) | 6 (30) |
| NSAID use at baseline, n (%) | 16 (80) |
| Previous TNFi therapy, n (%) | 2 (10) |
| HLA-B27 positive, n (%) | 14 (70) |
| Psoriasis, n (%) | 4 (20) |
| BASDAI, median (IQR) | 6.0 (5.1–6.7) |
| BASDAI-inflammation, median (IQR) | 5.4 (4.3–6.4) |
| BASFI, median (IQR) | 5.3 (4.0–7.0) |
| Pain (VAS), median (IQR) | 6.3 (6.0–7.8) |
| BASMI, median (IQR) | 2.5 (1.0–5.0) |
DMARD: disease-modifying antirheumatic drug; NSAID: nonsteroidal antiinflammatory drug; TNFi: tumor necrosis factor-α inhibitor; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; IQR: interquartile range; BASFI: Bath Ankylosing Spondylitis Functionality Index; VAS: visual analog scale; BASMI: Bath Ankylosing Spondylitis Metrology Index.